Staff Spotlight – Heidi Harmon, MD, MS

Dr. Harmon is Clinical Associate Professor in the Division of Neonatology and has the medical director of high risk follow-up program for almost a year.

My husband, Devon, and I have 2 boys- 9 and 12 years old. We are originally from Ohio but have most recently moved from Indianapolis. We also have 2 dogs- a lab mix and a lovable basset hound.

I enjoy gardening, photography, hiking, and travel.

My dream job would be to work for a NGO or nonprofit that works on improving child health outcomes when I retire.

Most fascinating place I’ve lived? I lived for 4 years in the Navajo Nation working for Indiana Health Service in Arizona.

Favorite food is Thai food or Indian, anything spicy.

I really like horror movies.

Fun fact: I played oboe through college but have not played once since graduation.

Dr. Aaron Boes Receives Career Development Award from the ANPA

Congratulations to Dr. Aaron Boes in the Division of Child Neurology for receiving the Sidney R. Baer Jr. Career Development Award from the American Neuropsychiatric Association (ANPA). This award is given annually, based on merits, to recognize a neuropsychiatry, behavioral neurology, or neuropsychology advanced trainee or faculty member within 5 years of completion of his/her post-graduate education whose outstanding accomplishments offer promise of a successful career in neuropsychiatry and the clinical neurosciences.

The award will be presented at the ANPA Annual Meeting.

Patient Story from Pediatric Neurology Epilepsy Clinic

When Anthony was six months old we were referred to pediatric neurology for questionable diagnosis of cerebral palsy. One month later, Anthony began having seizures. We began seeing Shelly Flynn, ARNP, in the pediatric neurology epilepsy clinic, and Anthony was then diagnosed with infantile spasms. And so began our journey into this whole new world, new life in University of Iowa Stead Family Children’s Hospital.

Continue reading

Dr. Starner Receives Awards for New Clinical Trials

Dr. Tim Starner received a couple new clinical trials award recently:

 

 

 

  • “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of VX-659 in Combination with Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)”, Vertex Pharmaceuticals, Inc. for $68,000.
  • “A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Theraphy in Subjects with Cystic Fibrosis Whoare Homozygous fo rthe F508del Mutation (F/F)”, Vertex Pharmaceuticals, Inc. for $58,000.